Posts tagged as: clinical trials back to homepage
 |
Fibrocell Submits Phase II Protocol for Burn Scars Treatment to FDA(0) Fibrocell Science, Inc. (OTCBB: FCSC), an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications, announced this morning that is has submitted to the U.S. Food & Drug Administration (FDA) the company’s Phase II clinical study protocol to evaluate the safety and efficacy of Fibrocell’s lead therapy, azficel-T, in improving the range of motion, function and flexibility, in patients with existing restrictive burn Read More |
 |
Cellceutix Secures $1 Million; Clinical Trials on Tap for Cancer Drug(0) Mass High Tech ran the story last Thursday after Cellceutix Corporation (OTCBB: CTIX) submitted a regulatory filing with the Security and Exchange Commission related to securing the funds, but this morning the company released press discussing their securing of $1 million in financing for their planned clinical trials on Kevetrin™, their flagship anti-cancer drug. The trials are slated to be held at Harvard’s Dana-Farber Cancer Institute. Read More |
 |
Cellceutix CEO Interview on TheStreetBeat Part II(0) Below is Part II of the CEO Interview from TheStreetBeat.com with Cellceutix CEO Leo Ehrlich, including the video and the text script. Read More |
|
Cellceutix CEO Leo Ehrlich Interviewed by TheStreetBeat.com(1) The latest edition of TheStreetBeat.com’s CEO Interview series features Cellceutix Chief Executive Officer Leo Ehrlich. The interview is being released in two parts, with Part One of the interview released this afternoon and Part Two slated Read More |
|
Cellceutix Novel Anti-Cancer Compound Kevetrin Presented at AACR Annual Meeting(0) Company on Schedule for Filing Amended IND - Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a biopharmaceutical company developing small molecule drugs to treat severe medical conditions, including drug-resistant cancers, is pleased to provide shareholders an update on developments with its novel anti-cancer compound Kevetrin™. Read More |
 |
Cellceutix Pens Agreement for Cancer Drug with Beth Israel Deaconess(0) Cellceutix Corporation (OTCBB:CTIX) continues to align itself with the biggest names in oncology research in the world. This truly sets the company apart from most of it developmental peers, regardless of exchange-listing or size. The company has released news recently about FDA document submissions seeking guidance on 505(b)(2) clearance for its psoriasis drug (which has provider stellar pre-clinical data) in addition to the clinical trials for its flagship cancer drug, Kevetrin™, which should be starting at Dana-Farber in the coming months. Read More |
350.png&w=160&h=120&zc=1&q=100) |
Cellceutix Files Pre-IND Documentation with FDA for New Psoriasis Drug(0) Company Gets Started on Next Drug in Their Pipeline Cellceutix Corporation (OTCBB: CTIX) (“the Company”), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, is pleased to report that it has filed a pre-IND submission with the U.S. Food and Drug Administration (FDA) on Prurisol™ (also termed “KM-133″), the Company’s drug in development as a novel treatment for psoriasis. Read More |
350.png&w=160&h=120&zc=1&q=100) |
OncoSec Dosing Merkel Cell Cancer Patients in Phase II Study(0) San Diego-based cancer researcher OncoSec Medical Inc. (OTCBB:ONCS) said that it has treated several patients in an open-label Phase II clinical trial evaluating its OncoSec Medical System (OMS) ElectroImmunotherapy for the treatment of Merkel cell carcinoma (MCC). The clinical trial is designed to test DNA IL-12 administered using OncoSec’s novel treatment approach for immunotherapy in patients with local and distant Merkel cell carcinoma, a rare and deadly skin cancer that currently Read More |
 |
Cellceutix Plans Clinical Trials for Psoriasis and Cancer Drugs in 2012(0) Cellceutix Corporation (OTCBB: CTIX) (“the Company”), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, is pleased to provide corporate updates on Kevetrin™, its novel drug in development for drug-resistant cancers, and KM-133, its compound being developed as a revolutionary psoriasis indication. Read More |
 |
BioTuesdays Says Cellceutix Better than Competition(0) Popular biotechnology website BioTuesdays.com published an article this morning on Cellceutix Corporation (OTCBB: CTIX) discussing the recent developments and significant potential of Cellceutix as a result of its cancer drug, Kevetrin, and other drugs in its pipeline. The article, titled “Cellceutix’s potential breakthrough in cancer research,” spends time noting the “Holy Grail” p53 connection Read More |
OTCBB News
read more
Stay Informed
Dana-Farber to Host Cellceutix Trials
Diabetes Rate Growing Exponentially
According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.
